Is Age-Related Macular Degeneration Hereditary?

Is Age-Related Macular Degeneration Hereditary?

Age-related macular degeneration has a strong hereditary component, but genes are only part of the story. Having a close relative with AMD significantly increases your risk, yet lifestyle factors such as smoking, diet, and cardiovascular health still play a major role in whether and how fast the disease develops.(1–4)

Key Facts at a Glance

• Twin and family studies estimate that 46–71% of the overall liability to AMD is explained by genetic factors, with higher heritability in advanced stages.(1–3)
• First‑degree relatives of people with AMD have roughly 2–4 times the risk of developing AMD compared with relatives of unaffected individuals.(4,5)
• Some clinic‑based data suggest up to a 10–12‑fold higher risk in siblings of affected patients, depending on age and smoking status.(5,6,7)
• Key risk genes include variants in CFH, ARMS2/HTRA1, and several complement and lipid pathway genes.(3,8,9)
• Even in monozygotic twins with identical DNA, differences in smoking, diet, and other exposures are associated with discordant AMD severity, underscoring the importance of environment.(2,3)
• Knowing your family history allows earlier eye examinations and targeted risk‑reduction strategies.(2,5–7)

Pathophysiology and Mechanism of Hereditary Risk

Age-related macular degeneration arises from complex interactions between genetic susceptibility and environmental exposures at the level of the retinal pigment epithelium (RPE), Bruch’s membrane, and the choriocapillaris.(3,8,9) Genome‑wide association studies have identified more than 30 loci associated with AMD, many of which cluster in pathways related to complement activation, lipid metabolism, extracellular matrix remodeling, and angiogenesis.(8,9)

The CFH (complement factor H) gene encodes a regulator that dampens alternative complement pathway activation on host tissues. The common CFH Y402H variant reduces this regulatory function, predisposing the RPE–Bruch’s membrane interface to chronic complement‑mediated inflammation.(8,9) Variants near ARMS2/HTRA1 on chromosome 10q26 are strongly associated with AMD and may alter extracellular matrix turnover, oxidative stress responses, and susceptibility to choroidal neovascularization.(8–10) Additional risk genes in C3, C2/CFB, CFI, APOE, and ABCA1 further illustrate the importance of complement and lipid handling in AMD pathogenesis.(8,9)

Genetic risk does not act in isolation. Oxidative stress from smoking, high‑fat diets, or mitochondrial dysfunction, together with age‑related changes in Bruch’s membrane, interact with genetic variants to promote drusen formation, RPE damage, and, in some individuals, neovascularization or geographic atrophy.(3,8–10)

Evidence from Twin Studies

Twin studies provide one of the clearest windows into heritability. The US Twin Study of Age‑Related Macular Degeneration examined 840 male twins (210 monozygotic and 181 dizygotic pairs) and found significant heritability estimates of 0.46 for overall AMD grade and 0.67–0.71 for intermediate and advanced AMD, respectively.(1,2) These values mean that nearly half to three‑quarters of the variability in AMD severity in that cohort could be attributed to additive genetic factors.(1,2)

A separate longitudinal twin study from Scandinavia reported similar findings, with monozygotic twins demonstrating much higher concordance for AMD than dizygotic twins, again supporting a strong genetic contribution.(1,3) Importantly, both studies also documented discordant cases—identical twins in which one had advanced AMD and the other did not—suggesting that environmental and stochastic factors significantly modify genetic predisposition.(2,3)

Familial Aggregation and Risk for Relatives

Beyond twins, family aggregation studies confirm that AMD clusters in families. A classic study by Seddon and colleagues compared first‑degree relatives of AMD patients with relatives of controls and found that medical‑record–confirmed age‑related maculopathy occurred in 23.7% of relatives of AMD probands versus 11.6% of control relatives, corresponding to an age‑ and sex‑adjusted odds ratio of 2.4 (95% CI 1.2–4.7).(4)

Subsequent work focusing on siblings of AMD patients reported even higher risks. One study found that 23% of siblings of advanced AMD cases had AMD themselves, with an odds ratio of 10.8, rising to 16.1 after adjusting for age.(5) Contemporary clinical guidance often summarizes this as “having a first‑degree relative with AMD increases your risk several‑fold,” with some sources quoting a roughly 3–12‑fold increased risk depending on study design and population.(5–7)

Key Genetic Variants and Their Clinical Relevance

Large genome‑wide association studies have refined our understanding of specific risk alleles. Variants in CFH and ARMS2/HTRA1 remain among the strongest single‑gene contributors; individuals carrying multiple risk alleles at these loci have substantially higher odds of developing advanced AMD compared with those with few or no risk alleles.(8–10,12)

Longitudinal cohort data suggest that combinations of CFH and ARMS2 risk alleles stratify progression risk from intermediate to late AMD.(11,12) For example, individuals with three or four high‑risk alleles across CFH and ARMS2 have significantly higher 10‑year progression rates than those with zero or one risk allele.(11,12) Despite this, genetic testing is not routinely required for AMD diagnosis or management, because clinical risk models that incorporate age, smoking, and fundus features already perform well, and treatment decisions (such as anti‑VEGF therapy) are usually based on phenotype rather than genotype.(9,11,12)

How Hereditary Risk Interacts with Lifestyle

Even in individuals with high genetic risk, environmental and lifestyle factors substantially influence whether AMD develops and how rapidly it progresses. Analyses of twin pairs discordant for AMD severity show that the affected twin is more likely to have smoked, had higher body mass index, or consumed a diet lower in antioxidants and omega‑3 fatty acids than the less affected twin.(2,3,9)

Large observational studies confirm that smoking roughly doubles the risk of AMD onset and progression, while higher adherence to Mediterranean‑style diets rich in leafy greens and fish is associated with lower risk, independent of genetic background.(9,13,14) Family history, therefore, should be viewed as a risk amplifier, not a deterministic fate: genes load the gun, but environment pulls the trigger.

What This Means for Patients and Families

If you have a parent, sibling, or child with age‑related macular degeneration, your personal risk is higher, but there are clear steps you can take:

• Inform your eye‑care provider about your family history and undergo regular dilated eye examinations, typically starting by age 50 or earlier if other risk factors are present.(2,5–7,9)
• Avoid smoking and second‑hand smoke; if you smoke, seek support to quit.(9,13)
• Adopt a diet emphasizing green leafy vegetables, coloured fruits, whole grains, and fish, consistent with Mediterranean patterns.(13,14)
• Follow evidence‑based recommendations for AREDS2 supplements if you are diagnosed with intermediate AMD or advanced disease in one eye.(14)
• Maintain cardiovascular health (blood pressure, cholesterol, weight), as these systemic factors may interact with genetic risk in AMD.(9,13)

Genetic counseling may be appropriate in families with multiple affected members or in patients interested in understanding their polygenic risk, although routine genetic testing is not yet standard of care.(9,11,12)

When to Consult a Specialist

You should see an optometrist or ophthalmologist—preferably with retina expertise—if you:

• Have a first‑degree relative with AMD and are over 50 years old.
• Notice central blur, distortion, difficulty reading, or a dark patch in your central vision.
• Already have early or intermediate AMD and want to understand your progression risk and preventive options.

Siblings and adult children of AMD patients should be informed of their increased risk and encouraged to seek eye examinations if they develop visual symptoms.(5–7)

Summary

Age-related macular degeneration is strongly influenced by heredity, with twin and genetic studies indicating that roughly half to three‑quarters of disease liability, particularly for advanced stages, is attributable to genetic factors. Having a first‑degree relative with AMD increases your risk several‑fold compared with the general population. However, environmental and lifestyle factors—including smoking, diet, and cardiovascular health—substantially modify this genetic predisposition, as evidenced by discordant twin pairs and family studies. Knowing your family history allows earlier, targeted surveillance and implementation of risk‑reduction strategies, meaning that a hereditary tendency to AMD does not inevitably lead to severe vision loss.

FAQs

If my parent has AMD, will I definitely get it?
No. A parent with AMD increases your risk but does not guarantee you will develop the disease.(2,4–7) Lifestyle choices such as not smoking and maintaining a healthy diet can significantly lower your overall risk.(9,13,14)

Should I have genetic testing for AMD risk genes?
Routine genetic testing is not currently recommended for most patients because results rarely change clinical management.(9,11,12) However, testing may be considered in research settings or for individuals who want more detailed risk information after counseling.

Are certain ethnic groups more affected by hereditary AMD?
AMD is more common in people of European ancestry, and many genetic studies have focused on these populations.(8,9,15) However, AMD also affects other ethnic groups, and both genetic and environmental factors are relevant across populations.(9,15)

Can AREDS2 supplements overcome a strong genetic risk?
AREDS2 formulations reduce progression risk in people with intermediate AMD regardless of genetic background, although some studies suggest genotype‑specific interactions.(11,12,14) Supplements should be used according to clinical criteria, not solely based on genetic results.

What should I tell my family if I have AMD?
Inform first‑degree relatives that they have a higher risk and should seek regular dilated eye exams, especially if they notice distortion or central blur.(5–7) Encourage them to avoid smoking and adopt a healthy diet to mitigate genetic risk.(9,13,14)

This article is for educational purposes only and reflects current scientific literature at the time of writing.

References

1. Hammond CJ, Webster AR, Snieder H, et al. Genetic and environmental factors in age-related maculopathy: a twin study. Ophthalmology. 2002;109(4):730–736. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC1298527
2. Seddon JM, Cote J, Page WF, et al. The US twin study of age-related macular degeneration: relative roles of genetic and environmental influences. Arch Ophthalmol. 2005;123(3):321–327. Available from: https://pubmed.ncbi.nlm.nih.gov/15767473
3. Meyers SM, Greene T, Gutman FA. A twin study of age-related macular degeneration. Am J Ophthalmol. 1995;120(6):757–766. Available from: https://pubmed.ncbi.nlm.nih.gov/9186125
4. Seddon JM, Ajani UA, Mitchell BD. Familial aggregation of age-related maculopathy. Ophthalmology. 1997;104(5):781–787. Available from: https://pubmed.ncbi.nlm.nih.gov/9186125
5. Seddon JM, Reynolds R, Rosner B. The importance of family history as a risk factor for age-related macular degeneration: a case-control study. Arch Ophthalmol. 2012;130(5):1–8. Summarized in: Chakravarthy U, et al. Br J Ophthalmol. 2012;96(9):1210–1213. Available from: https://pubmed.ncbi.nlm.nih.gov/21865200
6. Chakravarthy U, Augood C, Bentham GC, et al. Family history and age-related macular degeneration: results from the European Eye Study. Br J Ophthalmol. 2010;94(6):737–741. Available from: https://pubmed.ncbi.nlm.nih.gov/20472746
7. Cleveland Clinic. Does macular degeneration run in families? 2025. Available from: https://health.clevelandclinic.org/is-macular-degeneration-hereditary
8. Fritsche LG, Igl W, Bailey JNC, et al. A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. Nat Genet. 2016;48(2):134–143. Available from: https://academic.oup.com/hmg/article/26/R1/R45/3867129
9. Smith W, Assink J, Klein R, et al. Risk factors for age-related macular degeneration: pooled findings from three continents. Ophthalmology. 2001;108(4):697–704. Available from: https://pubmed.ncbi.nlm.nih.gov/11297486
10. Neureither M, Baasner A, Pauleikhoff D. Genetics of age-related macular degeneration. Dev Ophthalmol. 2014;53:33–54. Available from: https://amdbook.org/content/genetics-amd
11. Klein ML, Francis PJ, Ferris FL, et al. Risk alleles in CFH and ARMS2 and the long-term natural history of age-related macular degeneration. Ophthalmology. 2013;120(12):2587–2595. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC3602927
12. Vavvas DG, Small KW, Awh CC, et al. CFH and ARMS2 genetic risk determines progression to neovascular age-related macular degeneration after AREDS supplementation. Proc Natl Acad Sci U S A. 2018;115(11):E2569–E2578. Available from: https://www.pnas.org/doi/10.1073/pnas.1718059115
13. Chong EW, Robman LD, Simpson JA, et al. Diet and lifestyle factors for age-related macular degeneration: a systematic review and meta-analysis. Ophthalmology. 2009;116(9):1744–1754. Available from: https://pubmed.ncbi.nlm.nih.gov/19643491
14. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega‑3 fatty acids for age-related macular degeneration: the AREDS2 randomized clinical trial. JAMA. 2013;309(19):2005–2015. Available from: https://jamanetwork.com/journals/jama/fullarticle/1684847
15. Klein R, Klein BEK, Knudtson MD, et al. Prevalence of age-related macular degeneration in 4 racial/ethnic groups in the United States. Ophthalmology. 2006;113(3):373–380. Available from: https://pubmed.ncbi.nlm.nih.gov/16513455